Evidence map›Paper›PMID 39919903›Full record

ArticleAnnals of the rheumatic diseases2025

Precise identification and tracking of HMGCR-reactive CD4+ T cells in the target tissue of patients with anti-HMGCR immune-mediated necrotising myopathy.

Eleni Tiniakou, Alex Girgis, Tiara Siafei, Jemima Albayda, Brittany Adler, Julie J Paik, Christopher A Mecoli, Alison Rebman, Mark J Soloski, Lisa Christopher-Stine and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Eleni TiniakouDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address: etiniak1@jhmi.edu.
Alex GirgisDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Biomedical Engineering, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Tiara SiafeiDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Jemima AlbaydaDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Brittany AdlerDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Julie J PaikDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Christopher A MecoliDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Alison RebmanDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Mark J SoloskiDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Lisa Christopher-StineDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Kellie N SmithDepartment of Oncology and the Bloomberg-Kimmel Institute for Cancer Immunotherapy and Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Antony RosenDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.
Andrew Lee MammenDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; NIAMS/NIH, Bethesda, Maryland, USA; Division of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MS, USA.
Erika DarrahDivision of Rheumatology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA.

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026
$8.9M
RNA: Polymerase III specific CD8+ T cells: a mechanistic insight into cancer-induced autoimmunity in sclerodermaK08AR077732 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI TINIAKOU, ELENI · 2021 to 2025
$794k
Skeletal Myopathy in Systemic Sclerosis: Devising a Classification Schema Predictive of OutcomesK23AR073927 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PAIK, JULIE JISUN · 2020 to 2024
$787k
Optimizing the Approach to Identify Cancer-Associated MyositisK23AR075898 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI MECOLI, CHRISTOPHER · 2019 to 2023
$773k
NIAMS NIH HHS K08 AR077732NIAMS NIH HHS K23 AR073927NIAMS NIH HHS K23 AR075898NIAMS NIH HHS P30 AR070254
6 · The paper itself

Abstract

backgroundAnti-3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR)-positive immune-mediated necrotising myopathy (IMNM) is characterised by the presence of IgG autoantibodies against HMGCR and a strong association with specific HLA-DR alleles. Although these findings implicate HMGCR-specific CD4

methodsPeripheral blood mononuclear cells from patients with anti-HMGCR+IMNM (n=10) and dermatomyositis (DM; n=10) were stimulated with HMGCR protein and peptides identified using a natural antigen processing assay (NAPA; n=6). CD4

resultsCD4

conclusionHMGCR-antigen-reactive CD4

Indexed as

AutoantibodiesAutoimmune DiseasesCD4-Positive T-LymphocytesDermatomyositisHydroxymethylglutaryl CoA ReductasesMyositisAdultAgedFemaleHumansLymphocyte ActivationMaleMiddle AgedMuscle, SkeletalNecrosisAutoantibodiesHMGCR protein, humanHydroxymethylglutaryl CoA ReductasesAutoimmunityPolymyositisT-Lymphocytes

Identifiers

PMID39919903
PMCPMC11822226

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.